Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Gastroenterol Hepatol
Hauptverfasser: Meserve, Joseph, Aniwan, Satimai, Koliani-Pace, Jenna L., Shashi, Preeti, Weiss, Aaron, Faleck, David, Winters, Adam, Chablaney, Shreva, Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Bohm, Matthew, Sagi, Sashidhar Varma, Fischer, Monika, Lukin, Dana, Hudesman, David, Chang, Shannon, Gao, Youran, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/
https://ncbi.nlm.nih.gov/pubmed/30268561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge